Alnylam buys Sirna from Merck for $186mm up front, plus earn-outs
Alnylam Inc. (RNAi therapeutics for genetic diseases) acquired Merck & Co. Inc.’s Sirna Therapeutics Inc. RNAi division for $186mm up front, plus earn-outs and royalties.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.